Lakefront Biotherapeutics NV current report, Q4 FY2021

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV, a foreign private issuer, for the month of October 2021. The filing, dated October 6, 2021, incorporates by reference a press release issued on October 4, 2021 (Exhibit 99.1). The registrant is incorporated in Belgium and files annual reports on Form 20-F. Note: The request metadata references "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as Galapagos NV.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a conduit for a press release and does not contain a financial statement or quantitative performance data.

Material Changes

The filing does not disclose material changes in financial position or operations compared to prior periods. The primary content is the incorporation of a press release, the specific details of which are not included in the provided text.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, forward-looking guidance, risk factors, or descriptions of contingencies. It references a press release containing a quote from Dr. Walid Abi-Saab, but the content of that quote is excluded from the filing text provided.

Investor Verification Checklist

  • Verify the identity of the registrant (Galapagos NV) versus the metadata label (Lakefront Biotherapeutics NV).
  • Review the full text of Exhibit 99.1 (Press Release dated October 4, 2021) to understand the material event triggering this filing.
  • Confirm the specific content of the quote by Dr. Walid Abi-Saab mentioned in the filing.
  • Check subsequent filings for any financial data related to the event described in the press release.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.